We developed an innovative immunotherapeutic agent, a first-in-class PronectinTM-based Bispecific T-Cell Engager (pAXL×CD3ε), for the targeting of AXL, a TAM family tyrosine kinase receptor highly expressed in sarcomas. Here, NTRK1 is linked to sarcoma.